Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP621512.RAXUl86u8HMgNXibyB9rdVhlyQno_fRwz6IxTxbKWzaNI130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621512.RAXUl86u8HMgNXibyB9rdVhlyQno_fRwz6IxTxbKWzaNI130_provenance.
• NP622817.RASd1YyR_yLQt3Y9ldUfOIHlo1FNVtZlM0drWcpbUFucU130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622817.RASd1YyR_yLQt3Y9ldUfOIHlo1FNVtZlM0drWcpbUFucU130_provenance.
• NP654469.RASKkxiWGhQGErdqVMpHBz5mCQb7rDBUG_E4oDmUSC3Z8130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP654469.RASKkxiWGhQGErdqVMpHBz5mCQb7rDBUG_E4oDmUSC3Z8130_provenance.
• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1099072.RAaeuRy6SppqFjq4Z9tfD-bHPBHIvZqKrz_mRADwcZxG8130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099072.RAaeuRy6SppqFjq4Z9tfD-bHPBHIvZqKrz_mRADwcZxG8130_provenance.
• NP1099073.RAWI0Ofi6v6LD5JdhU_ZODyxtJJMgneBXEqVMBOzLj3ZY130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099073.RAWI0Ofi6v6LD5JdhU_ZODyxtJJMgneBXEqVMBOzLj3ZY130_provenance.
• NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP482917.RAASLho-5lCMd-av2e8gXiVCPJFgboKLlDrIL2oCEl1Rw130_provenance.
• NP624133.RAo8AqWbpPd8rfU5gOLxX4BP-XXigNm48VJNx6iiUn-Tg130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624133.RAo8AqWbpPd8rfU5gOLxX4BP-XXigNm48VJNx6iiUn-Tg130_provenance.
• NP625274.RAiPr7HlGsAsls9QBi0PYYTZJiJq5kexdUYOtQjJZlTBs130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625274.RAiPr7HlGsAsls9QBi0PYYTZJiJq5kexdUYOtQjJZlTBs130_provenance.
• NP258249.RAz-0CF3GGesZZSJD3SE3kH0iJx-9bdcBY7DWtc_rlK88130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP258249.RAz-0CF3GGesZZSJD3SE3kH0iJx-9bdcBY7DWtc_rlK88130_provenance.
• NP369499.RAy52hvH_3OW4UPE0hQ49xJQ64mSrQdgIklMKBnq2H9y4130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP369499.RAy52hvH_3OW4UPE0hQ49xJQ64mSrQdgIklMKBnq2H9y4130_provenance.
• NP1099065.RAKg0D6zyybYT3DLgmJMn14xmvVvmqerEtPE1l1mW66PM130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099065.RAKg0D6zyybYT3DLgmJMn14xmvVvmqerEtPE1l1mW66PM130_provenance.
• NP1099066.RAF30zsmytf1feV7dcI9rXVePfjtKXRo_e1gEUfp4mjWg130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099066.RAF30zsmytf1feV7dcI9rXVePfjtKXRo_e1gEUfp4mjWg130_provenance.
• NP1099067.RAKpy2kIl8jCv0dEn32L7zfNXHsvkWwdBBvgHNrJUGQD0130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099067.RAKpy2kIl8jCv0dEn32L7zfNXHsvkWwdBBvgHNrJUGQD0130_provenance.
• NP1099070.RANB-XizQNsDpFhUb1e2oRJ_pU1czTqdd3_xzPr_GGgJM130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099070.RANB-XizQNsDpFhUb1e2oRJ_pU1czTqdd3_xzPr_GGgJM130_provenance.
• NP1099071.RAOFYkNSEpQohstpgAzaiKbHm7K8fEyKKh5oBmVmquNUA130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099071.RAOFYkNSEpQohstpgAzaiKbHm7K8fEyKKh5oBmVmquNUA130_provenance.
• NP1099068.RAw-nELhs-MbQ0CL-quPkiZXFJ3bxZGMmkJJmWCISG8FE130_assertion description "[At present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1099068.RAw-nELhs-MbQ0CL-quPkiZXFJ3bxZGMmkJJmWCISG8FE130_provenance.